Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACXP Acurx Pharmaceuticals	$0.34 +2.2%	$0.45	$0.30 ▼ $2.39	$10.29M	-1.23	2.92 million shs	1.05 million shs
EGRX Eagle Pharmaceuticals	$3.69	$2.82	$1.50 ▼ $3.87	$47.92M	0.83	7,527 shs	N/A
JSPR Jasper Therapeutics	$2.95 -0.3%	$4.80	$2.27 ▼ $26.05	$44.01M	2.69	530,891 shs	85,493 shs
PEPG PepGen	$1.36 -1.4%	$1.38	$0.88 ▼ $12.47	$44.17M	1.16	1.35 million shs	65,208 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACXP Acurx Pharmaceuticals	-12.52%	-26.22%	-35.43%	-20.22%	-85.08%
EGRX Eagle Pharmaceuticals	0.00%	0.00%	+27.24%	+88.27%	-22.15%
JSPR Jasper Therapeutics	+0.34%	-9.48%	-46.67%	-44.98%	-83.97%
PEPG PepGen	0.00%	-5.48%	+24.32%	-6.12%	-91.87%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACXP Acurx Pharmaceuticals	2.361 of 5 stars	3.5	3.0	0.0	2.7	1.7	0.0
EGRX Eagle Pharmaceuticals	2.4165 of 5 stars	0.0	3.0	3.9	0.6	3.3	0.0
JSPR Jasper Therapeutics	3.6784 of 5 stars	4.3	4.0	0.0	3.1	1.7	0.6
PEPG PepGen	3.1957 of 5 stars	3.2	4.0	0.0	2.3	2.5	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACXP Acurx Pharmaceuticals	3.00	Buy	$8.00	2,273.89% Upside
EGRX Eagle Pharmaceuticals	0.00	N/A	N/A	N/A
JSPR Jasper Therapeutics	2.60	Moderate Buy	$29.75	908.47% Upside
PEPG PepGen	2.33	Hold	$7.67	463.73% Upside

Current Analyst Ratings Breakdown

Latest ACXP, EGRX, PEPG, and JSPR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/8/2025	JSPR Jasper Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Sector Perform	$5.00
7/8/2025	JSPR Jasper Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$70.00 ➝ $12.00
7/8/2025	JSPR Jasper Therapeutics	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$50.00 ➝ $20.00
7/8/2025	JSPR Jasper Therapeutics	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform
7/7/2025	JSPR Jasper Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$40.00 ➝ $20.00
7/7/2025	JSPR Jasper Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$64.00 ➝ $20.00
7/7/2025	JSPR Jasper Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Neutral
7/7/2025	JSPR Jasper Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform
5/29/2025	PEPG PepGen	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$14.00 ➝ $8.00
5/15/2025	ACXP Acurx Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy	$8.00
5/15/2025	JSPR Jasper Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$80.00 ➝ $65.00

(Data available from 7/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACXP Acurx Pharmaceuticals	N/A	N/A	N/A	N/A	$0.03 per share	N/A
EGRX Eagle Pharmaceuticals	$257.55M	0.19	$9.23 per share	0.40	N/A	∞
JSPR Jasper Therapeutics	N/A	N/A	N/A	N/A	$4.11 per share	N/A
PEPG PepGen	N/A	N/A	N/A	N/A	$3.64 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACXP Acurx Pharmaceuticals	-$14.10M	-$0.70	N/A	N/A	N/A	N/A	-526.78%	-223.78%	8/12/2025 (Estimated)
EGRX Eagle Pharmaceuticals	$35.64M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
JSPR Jasper Therapeutics	-$71.27M	-$5.24	N/A	N/A	N/A	N/A	-109.45%	-89.82%	8/12/2025 (Estimated)
PEPG PepGen	-$89.98M	-$3.13	N/A	N/A	N/A	N/A	-81.26%	-63.65%	8/14/2025 (Estimated)

Latest ACXP, EGRX, PEPG, and JSPR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	PEPG PepGen	-$0.8150	N/A	N/A	N/A	N/A	N/A
8/12/2025	Q2 2025	ACXP Acurx Pharmaceuticals	-$0.10	N/A	N/A	N/A	N/A	N/A
8/12/2025	Q2 2025	JSPR Jasper Therapeutics	-$1.28	N/A	N/A	N/A	N/A	N/A
5/12/2025	Q1 2025	ACXP Acurx Pharmaceuticals	-$0.14	-$0.11	+$0.03	-$0.11	N/A	N/A
5/12/2025	Q1 2025	JSPR Jasper Therapeutics	-$1.17	-$1.41	-$0.24	-$1.41	N/A	N/A
5/8/2025	Q1 2025	PEPG PepGen	-$0.72	-$0.92	-$0.20	-$0.92	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACXP Acurx Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
EGRX Eagle Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
JSPR Jasper Therapeutics	N/A	N/A	N/A	N/A	N/A
PEPG PepGen	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACXP Acurx Pharmaceuticals	N/A	1.93	1.93
EGRX Eagle Pharmaceuticals	N/A	N/A	N/A
JSPR Jasper Therapeutics	N/A	4.31	4.31
PEPG PepGen	N/A	4.95	4.95

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACXP Acurx Pharmaceuticals	11.53%
EGRX Eagle Pharmaceuticals	85.36%
JSPR Jasper Therapeutics	79.85%
PEPG PepGen	58.01%

Insider Ownership

Company	Insider Ownership
ACXP Acurx Pharmaceuticals	26.00%
EGRX Eagle Pharmaceuticals	28.90%
JSPR Jasper Therapeutics	4.60%
PEPG PepGen	5.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACXP Acurx Pharmaceuticals	3	30.52 million	22.59 million	Optionable
EGRX Eagle Pharmaceuticals	100	12.99 million	9.23 million	No Data
JSPR Jasper Therapeutics	20	15.02 million	14.33 million	Optionable
PEPG PepGen	30	32.72 million	31.02 million	Not Optionable

ACXP, EGRX, PEPG, and JSPR Headlines

Recent News About These Companies

Pomerantz Law Firm Announces the Filing of a Class Action Against PepGen Inc. and Certain Officers - PEPG

4 hours ago | prnewswire.com

PEPG Investors Have Opportunity to Lead PepGen Inc. Securities Fraud Lawsuit with the Schall Law Firm

5 hours ago | prnewswire.com

The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of PepGen Inc.(PEPG) Shareholders

5 hours ago | prnewswire.com

PEPG Deadline: PEPG Investors with Losses in Excess of $100K Have Opportunity to Lead PepGen Inc. Securities Fraud Lawsuit

July 30 at 5:42 PM | prnewswire.com

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of PepGen

July 30 at 5:41 PM | globenewswire.com

PepGen Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before August 8, 2025 to Discuss Your Rights – PEPG

July 30 at 4:25 PM | globenewswire.com

PepGen (NASDAQ:PEPG) Shares Down 3.5% - Here's Why

July 30 at 3:43 AM | americanbankingnews.com

PEPG INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that PepGen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

July 29 at 4:00 PM | globenewswire.com

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of PepGen

July 29 at 10:33 AM | prnewswire.com

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of August 8, 2025 in PepGen Inc. Lawsuit - PEPG

July 29 at 8:45 AM | prnewswire.com

PepGen Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. August 8,

July 28 at 10:29 PM | bakersfield.comB

Lost Money on PepGen Inc. (PEPG)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky

July 28 at 4:57 PM | theglobeandmail.com

PepGen Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. August 8, 2025 Deadline to file Lead Plaintiff Motion.

July 28 at 4:34 PM | globenewswire.com

Investors who lost money on PepGen Inc.(PEPG) should contact Levi & Korsinsky about pending Class Action - PEPG

July 28 at 4:05 PM | globenewswire.com

PEPG DEADLINE NOTICE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages PepGen Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important August 8 Deadline in Securities Class Action – PEPG

July 28 at 1:01 PM | globenewswire.com

DEADLINE ALERT: Holzer & Holzer, LLC Reminds Investors of August 8, 2025 Lead Plaintiff Deadline in the PepGen Inc. (PEPG) Class Action – Investors With Significant Losses Encouraged to Contact the Firm

July 28 at 12:35 PM | globenewswire.com

PEPG Deadline: Rosen Law Firm Urges PepGen Inc. (NASDAQ: PEPG) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights

July 28 at 12:35 PM | businesswire.com

Pomerantz Law Firm Announces the Filing of a Class Action Against PepGen Inc. and Certain Officers – PEPG

July 28 at 10:15 AM | globenewswire.com

PEPG Investors Have Opportunity to Lead PepGen Inc. Securities Fraud Lawsuit with the Schall Law Firm

July 28 at 9:34 AM | prnewswire.com

Contact The Gross Law Firm by August 8, 2025 Deadline to Join Class Action Against PepGen Inc.(PEPG)

July 28 at 8:45 AM | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACXP, EGRX, PEPG, and JSPR Company Descriptions

Acurx Pharmaceuticals NASDAQ:ACXP

$0.34 +0.01 (+2.18%)

As of 01:41 PM Eastern

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.

Eagle Pharmaceuticals NASDAQ:EGRX

$3.69 0.00 (0.00%)

As of 07/29/2025

Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.

Jasper Therapeutics NASDAQ:JSPR

$2.95 -0.01 (-0.34%)

As of 01:41 PM Eastern

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and conditioning regimens for stem cell transplantation. In addition, it is also developing stem cell transplants for rare diseases such as sickle cell disease, fanconi anemia, chronic granulomatous diseases, and GATA2 MDS, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.

PepGen NASDAQ:PEPG

$1.36 -0.02 (-1.45%)

As of 01:41 PM Eastern

PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients. The company is also developing PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 1 clinical trial for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. PepGen Inc. was founded in 2018 and is based in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time